Ultralife Corporation (ULBI) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerning aspects: a decline in operating income and net profit, decreased communication systems revenue, and increased operating expenses. The Q&A section highlights risks such as tariffs, cyber attack impacts, and lack of specific guidance on potential opportunities. While there is optimism about future growth, the lack of concrete figures and ongoing challenges contribute to a negative sentiment, likely resulting in a stock price decline.
Key Financial Performance
Q2 2025 Sales $48.6 million, an increase from $43 million in Q2 2024, driven by strong demand in government defense sales but offset by declines in medical battery and oil and gas sales.
Operating Income $2.3 million, down from $3.9 million in Q2 2024, due to a 57.2% decline in Communication Systems sales, lower gross margins in Battery & Energy products, and $0.3 million in one-time nonrecurring costs.
Net Profit $0.9 million ($0.05 EPS on GAAP basis), down from $2.7 million ($0.18 EPS) in Q2 2024, primarily due to lower operating income and higher interest expenses.
Revenues from Battery & Energy Products $45.9 million, up from $36.7 million in Q2 2024, with government defense sales increasing by 61.1% but offset by a 20.4% decline in commercial sales.
Revenues from Communication Systems $2.7 million, a 57.2% decline from $6.3 million in Q2 2024, due to large prior-year shipments and delayed purchase orders in 2025.
Gross Profit $11.6 million, flat compared to Q2 2024, with gross margin declining to 23.9% from 26.9% due to product mix, tariffs, and lower factory throughput.
Operating Expenses $9.3 million, a 22.2% increase from Q2 2024, driven by costs related to the Electrochem acquisition, increased new product development expenses, and one-time nonrecurring costs.
Adjusted EBITDA $4.1 million (8.5% of sales), down from $5.4 million (12.6% of sales) in Q2 2024, reflecting lower profitability and higher costs.
Debt Reduction $0.7 million repaid in Q2 2025, with $3.4 million repaid in the first half of 2025, exceeding the full-year amortization requirement of $2.8 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New ruggedized server case: Expanded portfolio to service new programs and server brands, providing greater market share in ruggedized computing environments.
3U portable server case: Completed and now available for orders.
DC power supply: Undergoing tests with multiple customers, expected contract awards soon.
20-Watt amplifier: Provides radio agnostic functionality, smallest and lightest in the market, in testing with partners, initial orders expected later this year.
Advanced speaker: Developed for a prime partner, initial shipments completing in 2025, expected to be a recurring revenue stream.
Thin cell technology: Initial production capabilities established for medical wearable and tracking applications, with several projects in qualification phase.
X5 medical care products: Pre-released portable power bank targeting tablet and portable computers, samples shipping now, production volumes available later this year.
Conformal wearable battery: Evolved as a commercial product, received new purchase order from a partner, expected to ship this year.
Government defense sales: Increased 61.1% due to strong demand from U.S.-based global prime.
Commercial sales: Decreased 20.4% due to declines in medical battery sales and oil and gas sales.
Domestic to international sales split: Shifted to 73-27 from 53-47 in 2024, reflecting heightened domestic shipments of government defense products.
Electrochem integration: Successfully transitioned ERP and office systems, manufacturing support systems to finalize in Q3.
Debt repayment: Ahead of schedule, with $0.7 million repaid in Q2 and $3.4 million in the first half of 2025.
Lean productivity projects: Completed a major project at Electrochem site, eliminating the need to hire 30 additional employees.
Vertical integration: Incorporating Electrochem cells into existing pack assemblies, broadening addressable market in oil and gas and other sectors.
Marketing improvements: Enhanced search engine optimization, targeted ads, and customer engagement to grow sales pipeline.
Focus on gross margin improvement: Initiatives include pricing adjustments, material cost deflation, and lean productivity projects.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariffs and Unfavorable Product Mix: The company faced direct headwinds from tariffs and unfavorable product mix shifts, negatively impacting gross margins.
Softness in Oil and Gas Business: Customers in the oil and gas sector were hesitant to commit to capital projects, leading to a 23.1% decline in sales in this segment.
Order Timing Challenges: Anticipated order timing challenges, particularly in the Communication Systems segment, negatively affected gross margin and revenue.
Decline in Communication Systems Revenue: Revenues from the Communication Systems segment declined 57.2% year-over-year due to delays in purchase orders and reduced demand from major international defense contractors.
Macroeconomic and Geopolitical Factors: Macroeconomic and geopolitical factors contributed to declines in medical battery sales (39%) and oil and gas sales (23.1%).
Higher Operating Expenses: Operating expenses increased by 22.2% year-over-year, driven by acquisition-related costs, new product development investments, and one-time nonrecurring expenses.
Gross Margin Decline: Consolidated gross margin declined by 300 basis points year-over-year due to product mix, tariffs, and lower factory throughput.
Interest Expense and Foreign Currency Fluctuations: Other expenses increased due to higher interest expenses from acquisition debt and the impact of foreign currency fluctuations.
Scaling and Tariff Impacts: Ongoing challenges with scaling operations and tariff impacts continue to pose risks to profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Sales and Revenue Growth: The company expects growth in sales and revenue in the second half of 2025 and into 2026, driven by new product launches, vertical integration opportunities, and an expanding sales pipeline across diversified markets including government defense, medical, and oil and gas.
Vertical Integration Benefits: Ultralife anticipates benefits from the vertical integration of Electrochem cells into existing pack assemblies, particularly in the oil and gas sector, with customer transitions expected to yield results in 2026.
New Product Development: Several new products are in development or testing phases, including ruggedized server cases, portable power banks, and advanced amplifiers. These products are expected to contribute to revenue growth starting in late 2025 and 2026.
Market Expansion: The company is expanding its addressable market in areas such as pipeline inspection, seismic telemetry, and sonobuoys, with new customer qualifications and product validations underway.
Operational Efficiency: Efforts to improve gross margins through pricing adjustments, material cost deflation, and lean productivity projects are ongoing, with expected positive impacts in the second half of 2025.
Defense Sector Growth: The Communications Systems Group is expected to rebound in the second half of 2025, supported by new product programs and increased global defense spending.
Medical and Oil & Gas Recovery: A rebound in medical and oil and gas customer demand is anticipated, with new product qualifications and customer transitions expected to drive growth in these sectors.
Long-Term Growth Initiatives: The company is focused on converting long-term development efforts into revenue, advancing vertical integration, and maintaining operational efficiency to sustain growth into 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Do you have any feel for what the tariffs cost you this past quarter?
A:The tariffs cost $539,482, less $126,000 received back from customers, resulting in a bottom-line hit of $400,000. The timing of component purchases during peak China tariffs exacerbated the impact.
Q:Based on what you know now with the current tariffs, how do you see that impacting the third quarter tariffs?
A:The current tariff rates are not expected to have as much impact as in Q2, as the exorbitant tariffs seen previously are not anticipated. However, the situation remains fluid. Additionally, a tariff surcharge is being passed on to customers.
Q:Regarding the employee retention credit that you received and applied to the debt, is there any more of that credit that's going to flow through in the balance of the year?
A:No, all of the employee retention credit, plus interest, has been captured.
Q:How much have you received so far from the insurance company for the cyber attack, and how much more are you looking to receive?
A:$235,000 has been received so far. The company has filed a lawsuit in the Supreme Court of Wayne County, seeking an amount in the millions for business interruption and impact. The trial is scheduled for mid-2026.
Q:Is the amount you are seeking in damages for the cyber attack disclosed in the complaint?
A:The amount is not disclosed in the court documents but may be included in discovery documents. Management offered to confirm and provide details if it becomes publicly disclosed.
Q:Is there anything to call out on orders returning or demand in the B&E Commercial segment, particularly in medical and oil and gas markets?
A:Oil and gas orders depend on indices like WTI and Brent. Customers are cautious with cash and order flow. Medical sales in Q2 2024 were the second-largest in company history, and management is optimistic about new product relationships and timing.
Q:Can you bucket the impacts on margins and explain visibility into higher-margin markets returning?
A:Tariffs cost 100 basis points of margin, mix impact caused almost 200 basis points, and other factors like material disposal and labor inefficiencies added 30-40 basis points. Management is optimistic about margin recovery as medical and oil and gas businesses improve and Comm Systems orders return.
Q:Can you quantify or provide certainty on the potential opportunities for later this year and next year?
A:Management is optimistic about multiple opportunities, each potentially adding $5-20 million in revenue. However, they lack concrete figures or paper in hand. They are focused on diversification and scaling the business.
Q:Have you ever had multiple large deals hit within the same year or two?
A:Not in recent memory, likely not since before 2010. However, management is positioning for such opportunities with investments in new products and long-term customer relationships.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the amount of damages sought in the cyber attack lawsuit, citing that it may be included in discovery documents. They also lacked concrete figures or timelines for potential revenue opportunities, using vague language about optimism and progress.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Act fund
CEO Director
CEO afternoon
CFO Treasurer
Communication System
Communication Systems
Conference Instructions
Conference PM
Conference today
Corporate Secretary
Deysher Pinnacle
Director Philip
ERP office
ET Ultralife
Electrochem Communication
Electrochem position
Energy product
Eric Deysher
Fain CFO
Form balance
Fund Lauber
Government defense
Lauber Unidentified
Manna
Mr Ultralife
Ultralife CEO
Ultralife Conference
afternoon Ultralife
debt agreement
gas sale
noncash
offering
sale decline
sale mix
system Ultralife
tariff
ULBI Transcript
Ultralife Corporation (ULBI) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call highlights strong financial performance with a 12% YoY revenue increase and improved margins, driven by demand in medical and defense sectors. Despite risks like economic conditions and potential military spending cuts, the company's operational efficiency and product mix improvements bolster sentiment. The absence of strategic updates or shareholder return plans limits the positivity, but the solid financials suggest a positive short-term stock reaction.
Ultralife Corporation (ULBI) Q4 2025 Earnings Call Transcript
Unknown3-10
The earnings call highlights a mixed financial performance with strong revenue growth in Battery & Energy Products but significant challenges in Communications Systems. Operational inefficiencies, delays in government contracts, and a net loss due to impairment charges weigh negatively. The Q&A section reveals management's lack of clarity on timelines for key projects, adding uncertainty. Despite some positive aspects like backlog growth and new medical orders, the overall sentiment is negative, especially given the financial losses and strategic risks.
Ultralife Corporation (ULBI) Q3 2025 Earnings Call Transcript
Unknown11-18
The earnings call presented mixed signals: strong revenue growth and new product development were offset by declining margins, increased operating expenses, and net losses. The absence of Q&A questions suggests no immediate analyst concerns, but macroeconomic factors and supply chain issues pose risks. With no clear catalyst for a strong move, the stock is likely to remain neutral in the short term.
Ultralife Corporation (ULBI) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call reveals several concerning aspects: a decline in operating income and net profit, decreased communication systems revenue, and increased operating expenses. The Q&A section highlights risks such as tariffs, cyber attack impacts, and lack of specific guidance on potential opportunities. While there is optimism about future growth, the lack of concrete figures and ongoing challenges contribute to a negative sentiment, likely resulting in a stock price decline.
ULBI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
